Library Open Repository

Technology evaluation: MRA, Chugai

Downloads

Downloads per month over past year

Ding, C and Jones, G (2003) Technology evaluation: MRA, Chugai. Current Opinion in Molecular Therapeutics, 5 (1). pp. 64-69. ISSN 1464-8431

[img]
Preview
PDF
MRA.PDF | Download (52kB)
Available under University of Tasmania Standard License.

Abstract

Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.

Item Type: Article
Journal or Publication Title: Current Opinion in Molecular Therapeutics
Page Range: pp. 64-69
ISSN: 1464-8431
Date Deposited: 28 Mar 2008 00:57
Last Modified: 18 Nov 2014 03:31
URI: http://eprints.utas.edu.au/id/eprint/3552
Item Statistics: View statistics for this item

Repository Staff Only (login required)

Item Control Page Item Control Page